Multivisceral resections for gastrointestinal stromal tumors: are the risks justifiable?

Surg Oncol. 2015 Mar;24(1):54-9. doi: 10.1016/j.suronc.2015.01.003. Epub 2015 Feb 4.

Abstract

Background: Surgical resection is the cornerstone of treatment for non-metastatic gastrointestinal stromal tumors (GISTs). Multivisceral resection (MVR) for locally advanced tumors is often required to achieve negative margins. The purpose of this study was to review the peri-operative and long-term oncologic outcomes for patients who required MVR versus single-organ resection (SOR) for GISTs.

Methods: All patients who underwent treatment for GISTs at a tertiary cancer center between 2001 and 2011 were identified. Patient characteristics and clinical outcomes were compared using the chi-squared/Fisher's exact test and Student's t-test. Disease-free (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier product-limit method.

Results: 33 patients underwent MVR and 77 underwent SOR. Tumors in the MVR group were larger and had a higher mitotic index. MVR patients had longer operative times, greater operative blood loss and more peri-operative complications. There was no significant difference in the final margin status between the two groups (R0 resection: SOR 92.2%, MVR 81.8%, p = 0.1303). 5-year DFS was significantly lower in the MVR cohort (44.4% vs. 78.9%, p = 0.0090), but there was no difference in 5-year OS (80.2% vs. 90.5%, p = 0.2547).

Conclusions: MVR patients had more aggressive tumors and more complications; however, there was no difference in 5-year OS between the MVR and SOR cohorts. These findings support the use of MVR in the appropriately selected patient. Further studies are necessary to fully define its clinical application.

Keywords: Gastrointestinal stromal tumors; Multivisceral resection; Perioperative outcomes; Survival.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Cancer Care Facilities
  • Digestive System Surgical Procedures
  • Female
  • Gastrointestinal Neoplasms* / drug therapy
  • Gastrointestinal Neoplasms* / pathology
  • Gastrointestinal Neoplasms* / surgery
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Gastrointestinal Stromal Tumors* / pathology
  • Gastrointestinal Stromal Tumors* / surgery
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local* / epidemiology
  • Neoplasm Recurrence, Local* / pathology
  • Ontario / epidemiology
  • Tertiary Care Centers
  • Treatment Outcome

Substances

  • Antineoplastic Agents